Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo by Theys, J, Pennington, O, Dubois, L, Anlezark, G, Vaughan, T, Mengesha, A, Landuyt, W, Anné, J, Burke, P J, Dûrre, P, Wouters, B G, Minton, N P, Lambin, P

Get full text

OC-0237: Adding Notch inhibition increases efficacy of standard of care treatment in glioblastoma by Yahyanejad, S, King, H, Iglesias, V, Granton, P, Barbeau, L, Van Hoof, S, Groot, A, Habets, R, Prickaerts, J, Chalmers, A, Theys, J, Short, S, Verhaegen, F, Vooijs, M

Get full text

Targeting NOTCH pathway in Glioblastoma by Yahyanejad, S, King, H, Iglesias, V.S, Granton, P.V, Barbeau, L. M.O, van Hoof, S.J, Groot, A.J, Habets, R, Prickaerts, J, Chalmers, A.J, Short, S.C, Verhaegen, F, Theys, J, Vooijs, M

Get full text

Hypoxia as a target for combined modality treatments by Wouters, B.G, Weppler, S.A, Koritzinsky, M, Landuyt, W, Nuyts, S, Theys, J, Chiu, R.K, Lambin, P

Get full text

214: NOTCH and radiotherapy: does it matter? by Vooijs, M, Sosa Iglesias, V, Habets, R, Theys, J

Get full text

Orthotopic tumor models for glioma and NSCLC by Theys, J, van Hoof, S, Sosa Iglesias, V, Schijns, L, Barbeau, L, Lieuwes, N, Dubois, L, Verhaegen, F, Vooijs, M

Get full text

EP-1351: Efficacy of combination treatments of a NOTCH inhibitor and chemoradiotherapy in an orthotopic glioma model by Yahyanejad, S, Granton, P.V, Van Hoof, S, Barbeau, L, Theys, J, Verhaegen, F, Vooijs, M

Get full text

OC-0236: DTP-006: a novel, orally bioavailable hypoxia-activated prodrug by Niemans, R, Yaromina, A, Theys, J, Ashoorzadeh, A, Anderson, R, Bull, M, Guise, C, Hsu, H.L, Abbattista, M, Mowday, A, Patterson, A.V, Smaill, J.B, Ackerley, D.F, Dubois, L, Lambin, P

Get full text

SP-0014: Radiation sensitivity and EMT in cancer: Role of the tumor microenvironment by Theys, J, Habets, R, Jutten, B, Groot, A, Paesmans, K, Lambin, P, Rouschop, K, Vooijs, M

Get full text

PO-428 Radiotherapy, immunocytokines and immune checkpoint inhibitors: finding the optimal combination by Pimentel, V Olivo, Marcus, D, Van der Wiel, A, Biemans, R, Lieuwes, NG, Neri, D, Theys, J, Yaromina, A, Dubois, LJ, Lambin, P

Get full text

Stable Escherichia coli-Clostridium acetobutylicum Shuttle Vector for Secretion of Murine Tumor Necrosis Factor Alpha by Theys, J, Nuyts, S, Landuyt, W, Van Mellaert, L, Dillen, C, Böhringer, M, Dürre, P, Lambin, P, Anné, J

Get full text

SP-0136: Off target effects with hypoxia activated prodrugs: lessons learned from PR-104A by Mowday, A., Dubois, L., Smaill, J., Patterson, A., Lambin, P., Theys, J.

Get full text

PD-0833 Exploiting tumor DNA repair status with the novel hypoxia-activated DNA alkylating agent CP-506 by van der Wiel, A., Yaromina, A., Lieuwes, N., Biemans, R., Theys, J., Dubois, L., Lambin, P.

Get full text

Insertion or Deletion of the Cheo Box Modifies Radiation Inducibility of Clostridium Promoters by NUYTS, S, VAN MELLAERT, L, BARBE, S, LAMMERTYN, E, THEYS, J, LANDUYT, W, BOSMANS, E, LAMBIN, P, ANNE, J

Get full text

OC-0065 Overcoming radioresistance with the hypoxia-activated prodrug CP-506: a pre-clinical in vivo study by Yaromina, A., Koi, L., van der Wiel, A., Lieuwes, N.G., Theys, J., Dubois, L., Krause, M., Lambin, P.

Get full text

OC-0203: Eliminating tumour hypoxia to improve the impact of immunotherapy by Marcus, D., Van der Wiel, A., Biemans, R., Lieuwes, N., Heyerick, A., Smaill, J., Patterson, A., Theys, J., Yaromina, A., Lambin, P., Dubois, L.

Get full text

Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression by Dubois, L, Dresselaers, T, Landuyt, W, Paesmans, K, Mengesha, A, Wouters, B G, Hecke, P Van, Theys, J, Lambin, P

Get full text

The Use of Radiation-Induced Bacterial Promoters in Anaerobic Conditions: A Means to Control Gene Expression in Clostridium-Mediated Therapy for Cancer by Nuyts, Sandra, Van Mellaert, Lieve, Theys, Jan, Landuyt, Willy, Lambin, Philippe, Anné, Jozef

Get full text

OC-0562: Exploiting tumor DNA repair status and hypoxia with CP-506, a novel hypoxia-activated prodrug by Van der Wiel, A., Marcus, D., Niemans, R., Yaromina, A., Theys, J., Mowday, A., Ashoorzadeh, A., Anderson, R., Bull, M., Abbattista, M., Heyerick, A., Guise, C., Smaill, J., Patterson, A., Dubois, L., Lambin, P.

Get full text

Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours by Lambin, P, Theys, J, Landuyt, W, Rijken, P, van der Kogel, A, van der Schueren, E, Hodgkiss, R, Fowler, J, Nuyts, S, de Bruijn, E, Van Mellaert, L, Anné, J

Get full text